In Brief: Vitacost Bends To Investors, Actavis Makes Asian Moves, DSM Courts Vitamin C Firm
This article was originally published in The Tan Sheet
Executive Summary
Truce for Vitacost, investors; Actavis buys Silom Medical; DSM courts Aland; ChromaDex shares product libraries; Tenn. blocks drug felons buying PSE; FTC finalizes L’Occitane settlement; and more In Brief.
You may also be interested in...
Vitacost Weighs Options After Losses; Shareholder Airs Complaints
Activist shareholder Consac urges Vitacost.com to sell after operating losses four years in a row, despite close to $400 million in annual sales.
FTC Settles Big With Sensa, Other Weight-Loss Marketers
FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.